← back to search

Robert Zielinski

Opole University of Technology · PL
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Radiopharmaceutical Chemistry and Applications, and Mechanical Circulatory Support Devices.
h-index
16
citations
2,657
works
76
NIH funding
primary concept
Medicine
email

Recent publications

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
The Lancet 2025cited by 42position: middledoi
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 23position: middledoi
Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers
JAMA Oncology 2025cited by 4position: middledoi
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
The Medical Journal of Australia 2024cited by 19position: middledoi
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
The Lancet Oncology 2023cited by 182position: middledoi
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology 2022cited by 53position: middledoi
Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021
Supportive Care in Cancer 2021cited by 77position: middledoi
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
Journal of Clinical Oncology 2021cited by 58position: middledoi
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
European Urology 2021cited by 48position: middledoi
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
New England Journal of Medicine 2019cited by 1,572position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

S.J. Harris · University of Central Florida2 papers (2024–2025)Matteo S. Carlino · Mater Health Services2 papers (2024–2025)Craig Underhill · Australian Research Council2 papers (2021–2025)Henry Marshall · University of Queensland1 papers (2025–2025)Muhammad Alamgeer · Monash University1 papers (2024–2024)Peter Grimison · Migration Institute of Australia1 papers (2021–2021)Andrew Martin · The University of Queensland1 papers (2022–2022) · 1 papers (2025–2025)Annette M. Lim · Peter MacCallum Cancer Centre1 papers (2024–2024)Rahul Ladwa · University of Queensland1 papers (2024–2024)Bryan Chan · Georgetown University1 papers (2021–2021)Damien Kee · Peter MacCallum Cancer Centre1 papers (2025–2025)Jonathan Cebon · University of Alabama at Birmingham1 papers (2025–2025) · 1 papers (2025–2025)John Park · California Baptist University1 papers (2024–2024) · 1 papers (2024–2024)Mathias Bressel · Peter MacCallum Cancer Centre1 papers (2024–2024)Ilse Mesters · Maastricht University1 papers (2021–2021)Brett Hughes · Australian Research Council1 papers (2024–2024)Oliver Klein · Profil Institute for Metabolic Research1 papers (2025–2025)